Key result
SGLT2 inhibitors fail to reduce HF readmissions but are linked to increased all-cause readmissions in frail patients.
Why the study?
Evidence is limited regarding the post-hospitalization effects of SGLT2 inhibitors in heart failure patients with reduced activities of daily living.
Does SGLT2 inhibitor prescription at discharge reduce heart failure rehospitalization and all-cause hospitalization in frail and non-frail patients with heart failure?
Population
188 patients with HF discharged without major interventions
Comparison
SGLT2 inhibitor prescription vs no SGLT2 inhibitor across frailty groups
Design
Single-center retrospective cohort study
Follow-up
One year
Authors
Loading...
SGLT2 inhibitors warrant caution at discharge in frail heart failure patients; leaves open confirmation of safety in randomized trials.
Cohort (n=188)
No
Does SGLT2 inhibitor prescription at discharge reduce heart failure rehospitalization and all-cause hospitalization in frail and non-frail patients with heart failure?
p-value: p=0.709
Suzuki et al. (2025) conducted a cohort in Heart Failure (n=188). SGLT2 inhibitors vs. No SGLT2 inhibitors was evaluated on Heart failure rehospitalization within one year (p=0.709). In patients with heart failure, SGLT2 inhibitors did not significantly reduce one-year heart failure rehospitalization, but significantly increased all-cause rehospitalization in frail patients with a Barthel Index <85.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: